Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $9.5500 (-6%) ($9.3800 - $9.9800) on Mon. Jun. 22, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 17.01% (three month average) | RSI | 25 | Latest Price | $9.5500(-6%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.8% a day on average for past five trading days. | Weekly Trend | ADAP declines -6.6% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) XLRE(23%) XBI(22%) IWC(21%) DRIV(20%) IBB(20%) | Factors Impacting ADAP price | ADAP will decline at least -8.505% in a week (0% probabilities). TLT(-13%) BNDX(-11%) TIP(-10%) VXX(-9%) FXI(-8%) | | | | | Relative Volatility | | | | Market Trend Strength | -8.505% (StdDev 17.01%) | Hourly BBV | 0 () | Intraday Trend | -4.3% | | | |
|
Resistance Level | $9.93 | 5 Day Moving Average | $10.05(-4.98%) | 10 Day Moving Average | $10.21(-6.46%) | 20 Day Moving Average | $9.93(-3.83%) | To recent high | -21.1% | To recent low | 84.7% | Market Cap | $1.477b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |